Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03893955 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Cancer and Advanced Solid Tumors, sponsored by AbbVie.
- Active
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT03893955: Active Phase 1 study of Cancer and Advanced Solid Tumors, sponsored by AbbVie.
NCT03893955 is a Phase 1 study of Cancer and Advanced Solid Tumors that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 150 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03893955, a Phase 1 study of Cancer and Advanced Solid Tumors, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. The dose-expansion phase can begin once the recommended phase 2 dose/maximum tolerated dose (RP2D/MTD) is determined in the dose-escalation phase.
Primary Outcome
ORR is defined as the percentage of participants with either complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Nab-paclitaxel
- DRUG ABBV-927
- DRUG ABBV-181
- DRUG ABBV-368
Study Locations (20)
North Carolina
- Duke Cancer Center /ID# 217641 - Durham
- Carolina BioOncology Institute /ID# 210664 - Huntersville
Texas
- Mary Crowley Cancer Research /ID# 210716 - Dallas
- NEXT Oncology /ID# 210717 - San Antonio
Other
- Centre Jean Perrin /ID# 217911 - Clermont-Ferrand
- AP-HP - Hopital Bichat - Claude-Bernard /ID# 212869 - Paris
Arkansas
- Highlands Oncology Group, PA /ID# 218863 - Springdale
California
- St Jude Hospital dba St Joseph /ID# 211130 - Santa Rosa
Connecticut
- Yale University School of Medicine /ID# 210678 - New Haven
Florida
- Moffitt Cancer Center /ID# 215037 - Tampa
Indiana
- Fort Wayne Medical Oncology and Hematology, Inc /ID# 226072 - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What the registry record for NCT03893955 still lists
NCT03893955 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower).
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT03893955 names 20 study sites across 17 states, led by North Carolina, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT03893955 about?
NCT03893955 is a clinical study titled "A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors". A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. ...
What is the current status of trial NCT03893955?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2019-05-21. Estimated completion is 2026-03.
What conditions does trial NCT03893955 study?
This clinical trial studies the following conditions: Cancer, Advanced Solid Tumors, Non-small Cell Lung Cancer (NSCLC), Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC).
What interventions are being tested in trial NCT03893955?
The interventions under investigation include: Carboplatin (DRUG), Nab-paclitaxel (DRUG), ABBV-927 (DRUG), ABBV-181 (DRUG), ABBV-368 (DRUG).
Who is sponsoring clinical trial NCT03893955?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03893955 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03893955's enrollment target sits among peer trials
150 264th of 615 higher than 346 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI